Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLA-matched multivirus-specific cytotoxic T lymphocytes
- Development stage
- Phase 2
- Lead developer
- Baylor College of Medicine
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
HLA-matched multivirus-specific cytotoxic T lymphocytes (VSTs) is an investigational cell therapy developed by the Center for Cell and Gene Therapy at Baylor College of Medicine. The therapy consists of allogeneic, banked, off-the-shelf T cells derived from healthy donors and expanded ex vivo to target immunodominant antigens from multiple viruses, specifically Epstein-Barr virus (EBV), cytomegalovirus (CMV), adenovirus (Adv), and BK virus. These polyclonal cells, containing both CD4+ and CD8+ T lymphocytes, are adoptively transferred to immunocompromised patients, such as hematopoietic stem cell transplant recipients, to restore antiviral immunity and treat persistent or refractory viral infections. Clinical data from the TETRAVI program has shown high response rates (approximately 67-92%) without significant graft-versus-host disease, providing a therapeutic option for patients who have failed conventional antiviral drugs.
- Other names
- Multivirus-specific cytotoxic T lymphocytesMultivirus-specific T cellsHLA-matched VSTsThird-party VSTsTetra-VSTs
02
Targets
pMHC-I (Peptide–MHC class I complex)pMHC (Peptide-MHC complex family)BK polyomavirus peptide–Human Leukocyte Antigen complexHAdV (Human adenovirus)
Beyond the preview
Go deeper on HLA-matched multivirus-specific cytotoxic T lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLA-matched multivirus-specific cytotoxic T lymphocytes.